You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Cancer
  5. Breast cancer

Lapatinib or trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone receptor-positive breast cancer that overexpresses HER2

  • Technology appraisal guidance
  • Reference number: TA257
  • Published:  27 June 2012
  • Guidance
  • Tools and resources
  • Information for the public
  • History

Information for the public

  • Lapatinib or trastuzumab in combination with an aromatase inhibitor for first treatment of metastatic breast cancer that is hormone-receptor and HER2 positive  (PDF 191 KB)

    Published:
    27 June 2012
  • Gwybodaeth i'r cyhoedd (Word 337 KB)

    Published:
    14 September 2012